五洲医疗(301234) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥138,023,356.31, a decrease of 6.35% compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2023 was ¥17,848,470.34, an increase of 2.15% year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥17,371,450.36, down 10.46% from the previous year[7]. - Total operating revenue for Q3 2023 reached ¥414,652,854.08, an increase of 4.15% compared to ¥396,005,110.69 in Q3 2022[22]. - Net profit for Q3 2023 was ¥54,046,043.52, representing a 10.5% increase from ¥48,947,073.37 in Q3 2022[24]. - Basic earnings per share for Q3 2023 were ¥0.7948, down from ¥0.8638 in Q3 2022, a decline of 7.9%[24]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥845,552,889.55, reflecting a slight increase of 0.12% from the end of the previous year[7]. - The company's total assets amounted to ¥845,552,889.55, slightly up from ¥844,564,374.07 in the previous quarter[21]. - Total liabilities decreased to ¥102,096,960.82 from ¥121,154,488.86, indicating a reduction of approximately 15.7%[21]. - Non-current assets totaled ¥331,586,149.45, a slight increase from ¥313,713,832.79[21]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥51,765,882.97, down 36.30% year-on-year[13]. - The cash flow from operating activities was ¥404,831,620.66, showing a slight decrease from ¥405,104,739.86 in the previous year[25]. - The net cash flow from operating activities for Q3 2023 was ¥51,765,882.97, a decrease of 36.2% compared to ¥81,263,629.63 in Q3 2022[26]. - The total cash inflow from investment activities was ¥593,168,161.45, significantly higher than ¥450,000.00 in the same period last year[26]. - The net cash flow from investment activities was ¥161,729,822.90, recovering from a negative cash flow of -¥115,800,794.90 in Q3 2022[26]. - The net cash flow from financing activities was -¥34,617,859.20, a decrease compared to a positive cash flow of ¥397,351,664.55 in Q3 2022[26]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,556[15]. - The largest shareholder, Huang Fan, holds 24.16% of shares, totaling 16,429,650 shares[15]. - The top 10 shareholders collectively hold significant stakes, with the top three shareholders owning a combined 53.41%[15]. - The company has no preferred shareholders as per the latest report[16]. - There were no changes in restricted shares during the reporting period, with a total of 1,428,000 shares being released[17]. Expenses and Investments - Sales expenses increased by 51.17% to ¥9,348,026.97 due to higher commissions, travel expenses, and advertising costs[12]. - Investment income for Q3 2023 was ¥3,492,204.42, a significant improvement compared to a loss of ¥4,204,960.00 in the same period last year[12]. - The company’s R&D expenses were ¥8,191,394.18, down from ¥9,492,628.04, indicating a reduction of approximately 13.7%[22]. - Cash paid for the purchase of fixed assets and other long-term assets was ¥53,881,978.55, a decrease from ¥107,722,996.81 in the previous year[26]. - The company paid ¥33,999,999.20 in dividends and interest, compared to ¥616,411.92 in Q3 2022[26]. Strategic Initiatives - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the report[18].